BCRX Annual EBITDA
-$117.99 M
+$25.86 M+17.98%
31 December 2023
Summary:
As of January 22, 2025, BCRX annual earnings before interest, taxes, depreciation & amortization is -$117.99 million, with the most recent change of +$25.86 million (+17.98%) on December 31, 2023. During the last 3 years, it has risen by +$49.58 million (+29.59%). BCRX annual EBITDA is now -2897.64% below its all-time high of -$3.94 million, reached on December 31, 2001.BCRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Quarterly EBITDA
$11.38 M
-$1.17 M-9.32%
30 September 2024
Summary:
As of January 22, 2025, BCRX quarterly earnings before interest, taxes, depreciation & amortization is $11.38 million, with the most recent change of -$1.17 million (-9.32%) on September 30, 2024. Over the past year, it has increased by +$49.54 million (+129.83%). BCRX quarterly EBITDA is now -26.49% below its all-time high of $15.48 million, reached on December 31, 2009.BCRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX TTM EBITDA
-$24.43 M
+$19.43 M+44.31%
30 September 2024
Summary:
As of January 22, 2025, BCRX TTM earnings before interest, taxes, depreciation & amortization is -$24.43 million, with the most recent change of +$19.43 million (+44.31%) on September 30, 2024. Over the past year, it has increased by +$91.91 million (+79.00%). BCRX TTM EBITDA is now -1778.92% below its all-time high of -$1.30 million, reached on March 31, 1994.BCRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.0% | +129.8% | +79.0% |
| 3 y3 years | +29.6% | +125.6% | +86.4% |
| 5 y5 years | -29.2% | +133.1% | +74.6% |
BCRX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +18.0% | -9.3% | +122.9% | at high | +83.0% |
| 5 y | 5-year | -22.6% | +29.6% | -9.3% | +120.8% | at high | +86.7% |
| alltime | all time | -2897.6% | +29.6% | -26.5% | +120.8% | -1778.9% | +86.7% |
BioCryst Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $11.38 M(-9.3%) | -$24.43 M(-44.3%) |
| June 2024 | - | $12.55 M(-223.0%) | -$43.86 M(-56.9%) |
| Mar 2024 | - | -$10.20 M(-73.3%) | -$101.68 M(-12.6%) |
| Dec 2023 | -$117.99 M(-18.0%) | -$38.16 M(+373.8%) | -$116.33 M(-5.3%) |
| Sept 2023 | - | -$8.05 M(-82.2%) | -$122.79 M(-6.0%) |
| June 2023 | - | -$45.26 M(+82.1%) | -$130.57 M(+9.8%) |
| Mar 2023 | - | -$24.86 M(-44.3%) | -$118.95 M(-17.3%) |
| Dec 2022 | -$143.85 M(+18.2%) | -$44.61 M(+181.7%) | -$143.85 M(+50.1%) |
| Sept 2022 | - | -$15.83 M(-52.9%) | -$95.82 M(-23.0%) |
| June 2022 | - | -$33.65 M(-32.4%) | -$124.44 M(+3.4%) |
| Mar 2022 | - | -$49.76 M(-1552.9%) | -$120.30 M(-1.2%) |
| Dec 2021 | -$121.74 M(-27.3%) | $3.42 M(-107.7%) | -$121.74 M(-32.3%) |
| Sept 2021 | - | -$44.46 M(+50.7%) | -$179.87 M(+1.0%) |
| June 2021 | - | -$29.50 M(-42.4%) | -$178.12 M(-3.3%) |
| Mar 2021 | - | -$51.20 M(-6.4%) | -$184.12 M(+10.1%) |
| Dec 2020 | -$167.56 M(+74.0%) | -$54.70 M(+28.1%) | -$167.25 M(+49.5%) |
| Sept 2020 | - | -$42.71 M(+20.3%) | -$111.90 M(+8.1%) |
| June 2020 | - | -$35.51 M(+3.4%) | -$103.56 M(+1.1%) |
| Mar 2020 | - | -$34.33 M(-5382.2%) | -$102.46 M(+6.4%) |
| Dec 2019 | -$96.28 M(+5.4%) | $650.00 K(-101.9%) | -$96.28 M(-20.9%) |
| Sept 2019 | - | -$34.37 M(-0.1%) | -$121.75 M(+6.4%) |
| June 2019 | - | -$34.41 M(+22.2%) | -$114.44 M(+19.1%) |
| Mar 2019 | - | -$28.15 M(+13.4%) | -$96.09 M(+5.2%) |
| Dec 2018 | -$91.31 M(+61.6%) | -$24.82 M(-8.3%) | -$91.31 M(+9.2%) |
| Sept 2018 | - | -$27.06 M(+68.5%) | -$83.62 M(+20.5%) |
| June 2018 | - | -$16.06 M(-31.3%) | -$69.38 M(+2.1%) |
| Mar 2018 | - | -$23.37 M(+36.4%) | -$67.94 M(+20.2%) |
| Dec 2017 | -$56.51 M(+17.3%) | -$17.13 M(+33.7%) | -$56.51 M(+35.9%) |
| Sept 2017 | - | -$12.82 M(-12.3%) | -$41.58 M(+7.6%) |
| June 2017 | - | -$14.62 M(+22.4%) | -$38.66 M(-0.4%) |
| Mar 2017 | - | -$11.95 M(+443.0%) | -$38.81 M(-19.4%) |
| Dec 2016 | -$48.17 M(+28.0%) | -$2.20 M(-77.8%) | -$48.17 M(-23.2%) |
| Sept 2016 | - | -$9.89 M(-33.1%) | -$62.73 M(-5.2%) |
| June 2016 | - | -$14.77 M(-30.7%) | -$66.18 M(+46.6%) |
| Mar 2016 | - | -$21.32 M(+27.2%) | -$45.15 M(+20.0%) |
| Dec 2015 | -$37.64 M(-5.9%) | -$16.75 M(+25.6%) | -$37.64 M(+20.6%) |
| Sept 2015 | - | -$13.34 M(-313.2%) | -$31.20 M(+23.1%) |
| June 2015 | - | $6.26 M(-145.3%) | -$25.34 M(-43.7%) |
| Mar 2015 | - | -$13.80 M(+33.8%) | -$44.98 M(+12.4%) |
| Dec 2014 | -$40.01 M(+59.9%) | -$10.32 M(+38.1%) | -$40.01 M(+18.3%) |
| Sept 2014 | - | -$7.47 M(-44.1%) | -$33.83 M(+2.2%) |
| June 2014 | - | -$13.38 M(+51.3%) | -$33.10 M(+8.0%) |
| Mar 2014 | - | -$8.84 M(+114.1%) | -$30.64 M(+22.4%) |
| Dec 2013 | -$25.03 M(-25.9%) | -$4.13 M(-38.8%) | -$25.03 M(-18.2%) |
| Sept 2013 | - | -$6.75 M(-38.2%) | -$30.60 M(-5.1%) |
| June 2013 | - | -$10.92 M(+238.2%) | -$32.25 M(-0.1%) |
| Mar 2013 | - | -$3.23 M(-66.7%) | -$32.29 M(-4.4%) |
| Dec 2012 | -$33.79 M(-35.4%) | -$9.71 M(+15.6%) | -$33.79 M(-12.1%) |
| Sept 2012 | - | -$8.40 M(-23.4%) | -$38.45 M(-9.9%) |
| June 2012 | - | -$10.96 M(+132.0%) | -$42.68 M(-6.7%) |
| Mar 2012 | - | -$4.72 M(-67.1%) | -$45.74 M(-12.5%) |
| Dec 2011 | -$52.29 M(+65.5%) | -$14.37 M(+13.9%) | -$52.29 M(+12.3%) |
| Sept 2011 | - | -$12.62 M(-10.0%) | -$46.55 M(+4.3%) |
| June 2011 | - | -$14.02 M(+24.4%) | -$44.61 M(+10.1%) |
| Mar 2011 | - | -$11.27 M(+30.6%) | -$40.52 M(+28.3%) |
| Dec 2010 | -$31.59 M(+160.5%) | -$8.63 M(-19.2%) | -$31.59 M(+322.8%) |
| Sept 2010 | - | -$10.68 M(+7.6%) | -$7.47 M(+5.3%) |
| June 2010 | - | -$9.93 M(+324.8%) | -$7.09 M(+29.3%) |
| Mar 2010 | - | -$2.34 M(-115.1%) | -$5.49 M(-54.8%) |
| Dec 2009 | -$12.12 M | $15.48 M(-250.3%) | -$12.12 M(-30.1%) |
| Sept 2009 | - | -$10.30 M(+23.7%) | -$17.34 M(+7.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$8.33 M(-7.3%) | -$16.20 M(-22.4%) |
| Mar 2009 | - | -$8.98 M(-187.4%) | -$20.87 M(-18.3%) |
| Dec 2008 | -$25.54 M(-17.4%) | $10.27 M(-212.0%) | -$25.54 M(-33.9%) |
| Sept 2008 | - | -$9.17 M(-29.5%) | -$38.62 M(-5.9%) |
| June 2008 | - | -$13.00 M(-4.7%) | -$41.04 M(+16.0%) |
| Mar 2008 | - | -$13.64 M(+385.5%) | -$35.38 M(+57.6%) |
| Dec 2007 | -$30.91 M(-33.1%) | -$2.81 M(-75.7%) | -$22.44 M(-25.6%) |
| Sept 2007 | - | -$11.59 M(+57.9%) | -$30.15 M(-13.5%) |
| June 2007 | - | -$7.34 M(+933.8%) | -$34.86 M(-9.0%) |
| Mar 2007 | - | -$709.80 K(-93.3%) | -$38.32 M(-17.0%) |
| Dec 2006 | -$46.17 M(+75.5%) | -$10.52 M(-35.4%) | -$46.17 M(+7.5%) |
| Sept 2006 | - | -$16.29 M(+50.9%) | -$42.93 M(+25.0%) |
| June 2006 | - | -$10.80 M(+26.1%) | -$34.35 M(+17.4%) |
| Mar 2006 | - | -$8.56 M(+17.6%) | -$29.27 M(+11.2%) |
| Dec 2005 | -$26.31 M(+26.5%) | -$7.28 M(-5.6%) | -$26.31 M(+8.6%) |
| Sept 2005 | - | -$7.71 M(+34.9%) | -$24.23 M(+11.5%) |
| June 2005 | - | -$5.71 M(+1.9%) | -$21.73 M(+3.5%) |
| Mar 2005 | - | -$5.61 M(+7.9%) | -$21.00 M(+1.0%) |
| Dec 2004 | -$20.79 M(+65.3%) | -$5.20 M(-0.3%) | -$20.79 M(+6.2%) |
| Sept 2004 | - | -$5.21 M(+4.5%) | -$19.58 M(+11.7%) |
| June 2004 | - | -$4.99 M(-7.6%) | -$17.52 M(+13.1%) |
| Mar 2004 | - | -$5.40 M(+35.6%) | -$15.49 M(+23.2%) |
| Dec 2003 | -$12.58 M(-27.9%) | -$3.98 M(+26.2%) | -$12.58 M(-4.5%) |
| Sept 2003 | - | -$3.15 M(+6.6%) | -$13.17 M(+0.4%) |
| June 2003 | - | -$2.96 M(+19.1%) | -$13.12 M(-12.9%) |
| Mar 2003 | - | -$2.48 M(-45.7%) | -$15.07 M(-15.9%) |
| Dec 2002 | -$17.46 M(+343.5%) | -$4.58 M(+47.4%) | -$17.92 M(+14.5%) |
| Sept 2002 | - | -$3.10 M(-36.7%) | -$15.64 M(+26.2%) |
| June 2002 | - | -$4.91 M(-8.0%) | -$12.39 M(+72.5%) |
| Mar 2002 | - | -$5.33 M(+131.2%) | -$7.18 M(+71.6%) |
| Dec 2001 | -$3.94 M(-57.0%) | -$2.31 M(-1678.8%) | -$4.19 M(-12.3%) |
| Sept 2001 | - | $146.00 K(-52.1%) | -$4.77 M(-29.0%) |
| June 2001 | - | $305.00 K(-113.1%) | -$6.72 M(-27.7%) |
| Mar 2001 | - | -$2.33 M(-19.4%) | -$9.29 M(+0.8%) |
| Dec 2000 | -$9.16 M(+20.6%) | -$2.89 M(+60.8%) | -$9.22 M(+6.9%) |
| Sept 2000 | - | -$1.80 M(-20.5%) | -$8.62 M(-7.5%) |
| June 2000 | - | -$2.27 M(+0.4%) | -$9.32 M(+26.6%) |
| Mar 2000 | - | -$2.26 M(-1.9%) | -$7.36 M(-1.9%) |
| Dec 1999 | -$7.60 M(+38.2%) | -$2.30 M(-8.0%) | -$7.51 M(+8.7%) |
| Sept 1999 | - | -$2.50 M(+711.4%) | -$6.91 M(+262.0%) |
| June 1999 | - | -$308.00 K(-87.2%) | -$1.91 M(-57.6%) |
| Mar 1999 | - | -$2.40 M(+41.2%) | -$4.50 M(-13.5%) |
| Dec 1998 | -$5.50 M(-53.0%) | -$1.70 M(-168.0%) | -$5.20 M(-23.5%) |
| Sept 1998 | - | $2.50 M(-186.2%) | -$6.80 M(-42.9%) |
| June 1998 | - | -$2.90 M(-6.5%) | -$11.90 M(+5.3%) |
| Mar 1998 | - | -$3.10 M(-6.1%) | -$11.30 M(-2.6%) |
| Dec 1997 | -$11.70 M(+42.7%) | -$3.30 M(+26.9%) | -$11.60 M(+1.8%) |
| Sept 1997 | - | -$2.60 M(+13.0%) | -$11.40 M(+2.7%) |
| June 1997 | - | -$2.30 M(-32.4%) | -$11.10 M(+12.1%) |
| Mar 1997 | - | -$3.40 M(+9.7%) | -$9.90 M(+19.3%) |
| Dec 1996 | -$8.20 M(-3.5%) | -$3.10 M(+34.8%) | -$8.30 M(+13.7%) |
| Sept 1996 | - | -$2.30 M(+109.1%) | -$7.30 M(+4.3%) |
| June 1996 | - | -$1.10 M(-38.9%) | -$7.00 M(-6.7%) |
| Mar 1996 | - | -$1.80 M(-14.3%) | -$7.50 M(-10.7%) |
| Dec 1995 | -$8.50 M(+37.1%) | -$2.10 M(+5.0%) | -$8.40 M(+3.7%) |
| Sept 1995 | - | -$2.00 M(+25.0%) | -$8.10 M(+6.6%) |
| June 1995 | - | -$1.60 M(-40.7%) | -$7.60 M(-1.3%) |
| Mar 1995 | - | -$2.70 M(+50.0%) | -$7.70 M(+22.2%) |
| Dec 1994 | -$6.20 M | -$1.80 M(+20.0%) | -$6.30 M(+40.0%) |
| Sept 1994 | - | -$1.50 M(-11.8%) | -$4.50 M(+50.0%) |
| June 1994 | - | -$1.70 M(+30.8%) | -$3.00 M(+130.8%) |
| Mar 1994 | - | -$1.30 M | -$1.30 M |
FAQ
- What is BioCryst Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual EBITDA year-on-year change?
- What is BioCryst Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly EBITDA year-on-year change?
- What is BioCryst Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM EBITDA year-on-year change?
What is BioCryst Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of BCRX is -$117.99 M
What is the all time high annual EBITDA for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$3.94 M
What is BioCryst Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, BCRX annual earnings before interest, taxes, depreciation & amortization has changed by +$25.86 M (+17.98%)
What is BioCryst Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of BCRX is $11.38 M
What is the all time high quarterly EBITDA for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $15.48 M
What is BioCryst Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, BCRX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$49.54 M (+129.83%)
What is BioCryst Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of BCRX is -$24.43 M
What is the all time high TTM EBITDA for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.30 M
What is BioCryst Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, BCRX TTM earnings before interest, taxes, depreciation & amortization has changed by +$91.91 M (+79.00%)